StockMacro
Menu

CareDx

$70.00 +225% in 6 monthsMarket cap $3.7B

CDNA on XNAS, Health Care, CareDx, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue rose 39% to $139.4M as the stock climbed 344% over 12 months.

  • BadShort interest 14% of shares, up 7.0% in two weeks
  • GoodInstitutional holders up 36% to 304 from 223 in the prior quarter

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Industry
Services-medical laboratories (Health Care)
Employees
765
Website
caredx.com
Listed
Nasdaq, US
Last results
29 Oct 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $139.4M, net income $19.3M.
Quarter to 31 Dec 2021: revenue $79.2M, net income -$16.2MQuarter to 31 Dec 2021: revenue $79.2M, net income -$16.2MQuarter to 31 Mar 2022: revenue $79.4M, net income -$19.6MQuarter to 31 Mar 2022: revenue $79.4M, net income -$19.6MQuarter to 30 Jun 2022: revenue $80.6M, net income -$21.7MQuarter to 30 Jun 2022: revenue $80.6M, net income -$21.7MQuarter to 30 Sep 2022: revenue $79.4M, net income -$16.9MQuarter to 30 Sep 2022: revenue $79.4M, net income -$16.9MQuarter to 31 Dec 2022: revenue $82.4M, net income -$18.3MQuarter to 31 Dec 2022: revenue $82.4M, net income -$18.3MQuarter to 31 Mar 2023: revenue $77.3M, net income -$23.7MQuarter to 31 Mar 2023: revenue $77.3M, net income -$23.7MQuarter to 30 Jun 2023: revenue $70.3M, net income -$25.0MQuarter to 30 Jun 2023: revenue $70.3M, net income -$25.0MQuarter to 30 Sep 2023: revenue $67.2M, net income -$23.5MQuarter to 30 Sep 2023: revenue $67.2M, net income -$23.5MQuarter to 31 Dec 2023: revenue $65.6M, net income -$118.1MQuarter to 31 Dec 2023: revenue $65.6M, net income -$118.1MQuarter to 31 Mar 2024: revenue $72.0M, net income -$16.7MQuarter to 31 Mar 2024: revenue $72.0M, net income -$16.7MQuarter to 30 Jun 2024: revenue $92.3M, net income -$1.4MQuarter to 30 Jun 2024: revenue $92.3M, net income -$1.4MQuarter to 30 Sep 2024: revenue $82.9M, net income -$7.4MQuarter to 30 Sep 2024: revenue $82.9M, net income -$7.4MQuarter to 31 Dec 2024: revenue $86.6M, net income $78.0MQuarter to 31 Dec 2024: revenue $86.6M, net income $78.0MQuarter to 31 Mar 2025: revenue $84.7M, net income -$10.4MQuarter to 31 Mar 2025: revenue $84.7M, net income -$10.4MQuarter to 30 Jun 2025: revenue $86.7M, net income -$8.6MQuarter to 30 Jun 2025: revenue $86.7M, net income -$8.6MQuarter to 30 Sep 2025: revenue $100.1M, net income $1.7MQuarter to 30 Sep 2025: revenue $100.1M, net income $1.7MQuarter to 31 Dec 2025: revenue $108.4M, net income -$4.1MQuarter to 31 Dec 2025: revenue $108.4M, net income -$4.1MQuarter to 31 Mar 2026: revenue $117.7M, net income $2.8MQuarter to 31 Mar 2026: revenue $117.7M, net income $2.8MQuarter to 30 Jun 2026: revenue $131.9M, net income $110.6MQuarter to 30 Jun 2026: revenue $131.9M, net income $110.6MQuarter to 30 Sep 2026: revenue $139.4M, net income $19.3MQuarter to 30 Sep 2026: revenue $139.4M, net income $19.3M
31 Dec 2021RevenueNet incomeNet losstallest bar $139.4M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$139.4M$19.3M
30 Jun 2026$131.9M$110.6M
31 Mar 2026$117.7M$2.8M
31 Dec 2025$108.4M-$4.1M
30 Sep 2025$100.1M$1.7M
30 Jun 2025$86.7M-$8.6M
31 Mar 2025$84.7M-$10.4M
31 Dec 2024$86.6M$78.0M
30 Sep 2024$82.9M-$7.4M
30 Jun 2024$92.3M-$1.4M
31 Mar 2024$72.0M-$16.7M
31 Dec 2023$65.6M-$118.1M
30 Sep 2023$67.2M-$23.5M
30 Jun 2023$70.3M-$25.0M
31 Mar 2023$77.3M-$23.7M
31 Dec 2022$82.4M-$18.3M
30 Sep 2022$79.4M-$16.9M
30 Jun 2022$80.6M-$21.7M
31 Mar 2022$79.4M-$19.6M
31 Dec 2021$79.2M-$16.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $497.4M $358.0M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +39% +17%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $128.6M $60.8M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $2.39 $1.10
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 33.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 23.4% 14.0% -8.2%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 25.9% 17.0% -5.9%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 33.0% -10.1%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $250.5M $194.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$250.5M (net cash) -$194.2M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.16
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $8.90
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 28.6 29.1
P/SPrice to sales: market cap divided by revenue of the last 12 months. 7.4 3.6
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 6.9 2.6
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 7.9 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
CareDxCDNA (this company) $3.7B28.67.4+39%25.9%
BillionToOneBLLN $4.3B87.09.8+72%11.3%
GRAILGRAL $4.5Bloss26.8+17%-244%
Caris Life SciencesCAI $5.0B52.54.8+61%9.2%
CelcuityCELC $2.6Bloss–––
RadNetRDNT $5.5Bloss2.3+21%-0.9%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$6.8M

bought $0, sold $6.8M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+36%

304 13F filers vs 223

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

99%

51.9M shares held by 13F filers (30 Sep 2026) of 52.5M outstanding (26 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

14%

7.2M shares sold short (30 Oct 2026) of 52.5M outstanding (26 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

5.3

7.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+7.0%

6.7M shares sold short in the report before, 7.2M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

34%

34% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 52%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

61

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-53%

7 vs 15 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+39%

$139.4M vs $100.1M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+24%

$1.6M vs $1.3M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$4.4M

the 12 months before: $3.6M

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$370K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

24

24 articles in the last 7 days; its usual week has 3.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

6.9×

24 articles in the last 7 days; its usual week has 3.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • New institutional positions 96, 3.0× a year earlier
  • Revenue $139.4M, 1.4× a year earlier

Price $70.00 on 20 Nov 2026, +344% over 12 months (12-month range $15.76 to $88.47)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $20.1M in the last 12 months (the 12 months before: -$3.3M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 7 published in the last 12 months, -53% on the 12 months before.
Revenue per quarter. Revenue $139.4M in the latest quarter, +39% on a year earlier.
Capital spending per quarter. Capital spending $1.6M in the latest quarter, +24% on a year earlier.
Institutional holders (13F filers). 304 13F filers reported holding it in the latest 13F quarter, +73% on a year earlier.
Federal obligations. Federal obligations: $7.1M published in the last 12 months, +224% on the 12 months before.
Lobbying spend. Lobbying spend: $435K published in the last 12 months, +98% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Nov 2026Sharp changeMany funds opening a new position: many funds opening a new position, 96 vs usual 33 (2026-09-30); 3.0x the same period a year earlier
16 Nov 2026Lobbying filingnew lobbying registration (TIBER CREEK GROUP)
3 Nov 2026Sharp changeQuarterly revenue change: quarterly revenue change, 139.4M vs usual 93.4M (2026-09-30); 1.4x the same period a year earlier
4 Aug 2026Sharp changeQuarterly revenue change: quarterly revenue change, 131.9M vs usual 89.5M (2026-06-30); 1.5x the same period a year earlier
7 Jul 20268-K and other filingsCompleted an acquisition or asset sale
15 Jun 20268-K and other filingsDirector or officer change
15 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Apr 2026Sharp changeQuarterly revenue change: quarterly revenue change, 117.7M vs usual 86.6M (2026-03-31); 1.4x the same period a year earlier
24 Oct 20258-K and other filingsDirector or officer change
20 Oct 2025Lobbying filinglobbying engagement terminated (CURA STRATEGIES)
13 Oct 2025Lobbying filinglobbying engagement terminated (NET CENTRIC ALLIANCE LLC)
15 Sep 2025Lobbying filingnew lobbying registration (in-house)
6 Aug 20258-K and other filingsDirector or officer change
20 Jul 2025Lobbying filinglobbying engagement terminated (ACTUM I, LLC)
12 Jun 20258-K and other filingsDirector or officer change
14 May 2025Lobbying filinglobbying engagement terminated (MR. MATTHEW R. SIMMONS)
28 Mar 20258-K and other filingsDirector or officer change
8 Jan 20258-K and other filingsDirector or officer change
8 Jan 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Nov 2024Sharp changeMany funds opening a new position: many funds opening a new position, 59 vs usual 18.50 (2024-09-30); 4.9x the same period a year earlier
4 Oct 20248-K and other filingsDirector or officer change
12 Sep 20248-K and other filingsDirector or officer change
12 Sep 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Jul 2024Lobbying filinglobbying engagement terminated (TGB STRATEGIES LLC)
16 Apr 20248-K and other filingsDirector or officer change
11 Mar 20248-K and other filingsDirector or officer change
12 Feb 2024Lobbying filingnew lobbying registration (MR. MATTHEW R. SIMMONS)
22 Jan 2024Lobbying filingnew lobbying registration (NET CENTRIC ALLIANCE LLC)
9 Jan 2024Lobbying filingnew lobbying registration (ACTUM I, LLC)
22 Dec 20238-K and other filingsDirector or officer change
1 Nov 20238-K and other filingsDirector or officer change
1 Oct 2023Sharp changeFirst federal award: first federal award: CAREDX, INC.: new Department of Veterans Affairs contract 36C25223N0621 ($1,022,670)
26 Sep 20238-K and other filingsDirector or officer change
26 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Nov 20228-K and other filingsDirector or officer change
7 Sep 20228-K and other filingsDirector or officer change
1 Sep 20228-K and other filingsDirector or officer change
1 Sep 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 May 20228-K and other filingsDirector or officer change
23 May 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Mar 2022Lobbying filingnew lobbying registration (TGB STRATEGIES LLC)
Insider net buying (open market)
Month from 1 Nov 2021: $212K published
Month from 1 Dec 2021: -$439K published
Month from 1 Jan 2022: -$660K published
Month from 1 Feb 2022: -$924K published
Month from 1 Mar 2022: -$1.6M published
Month from 1 Apr 2022: -$404K published
Month from 1 May 2022: -$119K published
Month from 1 Aug 2022: -$556K published
Month from 1 Jan 2023: -$33K published
Month from 1 Feb 2023: -$546K published
Month from 1 Mar 2023: -$45K published
Month from 1 Apr 2023: -$25K published
Month from 1 May 2023: -$23K published
Month from 1 Jun 2023: -$169K published
Month from 1 Jul 2023: -$130K published
Month from 1 Aug 2023: -$37K published
Month from 1 Sep 2023: -$27K published
Month from 1 Oct 2023: -$19K published
Month from 1 Aug 2024: -$4.3M published
Month from 1 Dec 2024: -$325K published
Month from 1 Feb 2025: -$82K published
Month from 1 Mar 2025: -$367K published
Month from 1 Apr 2025: -$21K published
Month from 1 May 2025: -$1.5M published
Month from 1 Jun 2025: -$781K published
Month from 1 Jul 2025: -$186K published
Month from 1 Aug 2025: -$34K published
Month from 1 Nov 2025: -$42K published
Month from 1 Dec 2025: -$140K published
Month from 1 Jan 2026: -$626K published
Month from 1 Feb 2026: -$91K published
Month from 1 Apr 2026: -$217K published
Month from 1 May 2026: -$270K published
Month from 1 Jun 2026: -$1.3M published
Month from 1 Jul 2026: -$6.7M published
Month from 1 Aug 2026: -$3.9M published
Month from 1 Nov 2026: -$6.8M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 5 published
Quarter from 1 Apr 2022: 14 published
Quarter from 1 Jul 2022: 2 published
Quarter from 1 Oct 2022: 2 published
Quarter from 1 Jan 2023: 1 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Oct 2023: 1 published
Quarter from 1 Jan 2024: 2 published
Quarter from 1 Apr 2024: 1 published
Quarter from 1 Jul 2024: 4 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Jan 2025: 4 published
Quarter from 1 Apr 2025: 1 published
Quarter from 1 Jul 2025: 4 published
Quarter from 1 Oct 2025: 6 published
Quarter from 1 Apr 2026: 3 published
Quarter from 1 Jul 2026: 4 published
Revenue per quarter
Quarter ended 31 Dec 2021: $79.2M, +35% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $79.4M, +18% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $80.6M, +8.7% on a year earlier; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $79.4M, +5.0% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $82.4M, +4.0% on a year earlier; public on 28 Feb 2023
Quarter ended 31 Mar 2023: $77.3M, -2.7% on a year earlier; public on 11 May 2023
Quarter ended 30 Jun 2023: $70.3M, -13% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $67.2M, -15% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $65.6M, -20% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2024: $72.0M, -6.7% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $92.3M, +31% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $82.9M, +23% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $86.6M, +32% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $84.7M, +18% on a year earlier; public on 1 May 2025
Quarter ended 30 Jun 2025: $86.7M, -6.1% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $100.1M, +21% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $108.4M, +25% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $117.7M, +39% on a year earlier; public on 29 Apr 2026
Quarter ended 30 Jun 2026: $131.9M, +52% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $139.4M, +39% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Mar 2025: $1.6M; public on 29 Apr 2026
Quarter ended 30 Jun 2025: $1.0M; public on 31 Jul 2026
Quarter ended 30 Sep 2025: $1.3M; public on 30 Oct 2026
Quarter ended 31 Mar 2026: $3.8M, +134% on a year earlier; public on 29 Apr 2026
Quarter ended 30 Jun 2026: $1.9M, +85% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $1.6M, +24% on a year earlier; public on 30 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 208; public on 14 Feb 2022
31 Mar 2022 report: 203; public on 16 May 2022
30 Jun 2022 report: 174; public on 15 Aug 2022
30 Sep 2022 report: 170; public on 14 Nov 2022
31 Dec 2022 report: 158; public on 14 Feb 2023
31 Mar 2023 report: 152; public on 15 May 2023
30 Jun 2023 report: 146; public on 14 Aug 2023
30 Sep 2023 report: 139; public on 14 Nov 2023
31 Dec 2023 report: 137; public on 14 Feb 2024
31 Mar 2024 report: 142; public on 15 May 2024
30 Jun 2024 report: 148; public on 14 Aug 2024
30 Sep 2024 report: 207; public on 14 Nov 2024
31 Dec 2024 report: 205; public on 14 Feb 2025
31 Mar 2025 report: 210; public on 15 May 2025
30 Jun 2025 report: 189; public on 14 Aug 2025
30 Sep 2025 report: 176; public on 14 Nov 2025
31 Dec 2025 report: 194; public on 17 Feb 2026
31 Mar 2026 report: 185; public on 15 May 2026
30 Jun 2026 report: 223; public on 14 Aug 2026
30 Sep 2026 report: 304; public on 16 Nov 2026
Federal obligations
Month from 1 Feb 2022: -$3K published
Month from 1 Mar 2022: $138K published
Month from 1 Apr 2022: $0 published
Month from 1 May 2022: -$29K published
Month from 1 Jun 2022: $190K published
Month from 1 Aug 2022: $847K published
Month from 1 Sep 2022: $431K published
Month from 1 Oct 2022: $606K published
Month from 1 Dec 2022: $602K published
Month from 1 Feb 2023: $138K published
Month from 1 Mar 2023: $65K published
Month from 1 Jun 2023: -$133K published
Month from 1 Jul 2023: $617K published
Month from 1 Sep 2023: $383K published
Month from 1 Oct 2023: $1.1M published
Month from 1 Nov 2023: $243K published
Month from 1 Dec 2023: $343K published
Month from 1 Jan 2024: $57K published
Month from 1 Feb 2024: $124K published
Month from 1 Mar 2024: -$86K published
Month from 1 May 2024: $175K published
Month from 1 Jun 2024: $39K published
Month from 1 Jul 2024: $1.2M published
Month from 1 Aug 2024: -$626K published
Month from 1 Oct 2024: $2.8M published
Month from 1 Jan 2025: $54K published
Month from 1 Feb 2025: $138K published
Month from 1 Mar 2025: -$10K published
Month from 1 Apr 2025: $522K published
Month from 1 May 2025: -$20K published
Month from 1 Jun 2025: $250K published
Month from 1 Jul 2025: $492K published
Month from 1 Aug 2025: -$9K published
Month from 1 Sep 2025: $814K published
Month from 1 Oct 2025: $48K published
Month from 1 Nov 2025: -$77K published
Month from 1 Jan 2026: $1.7M published
Month from 1 Feb 2026: $796K published
Month from 1 Apr 2026: -$71K published
Month from 1 Jun 2026: $0 published
Month from 1 Jul 2026: $1.0M published
Month from 1 Aug 2026: $185K published
Month from 1 Sep 2026: $2.5M published
Month from 1 Oct 2026: $865K published
Month from 1 Nov 2026: $112K published
Lobbying spend
Quarter from 1 Jan 2022: $55K published
Quarter from 1 Apr 2022: $165K published
Quarter from 1 Jul 2022: $158K published
Quarter from 1 Oct 2022: $90K published
Quarter from 1 Jan 2023: $90K published
Quarter from 1 Apr 2023: $130K published
Quarter from 1 Jul 2023: $150K published
Quarter from 1 Oct 2023: $156K published
Quarter from 1 Jan 2024: $223K published
Quarter from 1 Jul 2024: $240K published
Quarter from 1 Oct 2024: $418K published
Quarter from 1 Apr 2025: $80K published
Quarter from 1 Jul 2025: $50K published
Quarter from 1 Oct 2025: $90K published
Quarter from 1 Jan 2026: $175K published
Quarter from 1 Apr 2026: $140K published
Quarter from 1 Jul 2026: $90K published
Quarter from 1 Oct 2026: $30K published

What is unusual now

  • Made public in the last 90 days: it saw 96 13F filers open a new position in the quarter ended 30 Sep 2026, 3.0× the same quarter last year; it also reported revenue of $139.4M for the quarter ended 30 Sep 2026, 1.4× the same quarter last year. Two or more unrelated kinds of activity agreed on 17 Nov 2026.
  • Many funds opening a new position: saw 96 13F filers open a new position in the quarter ended 30 Sep 2026, 3.0× the same quarter last year Public on 16 Nov 2026.
  • Quarterly revenue change: reported revenue of $131.9M for the quarter ended 30 Jun 2026, 1.5× the same quarter last year Public on 4 Aug 2026.
  • Insider net buying (open market): Insiders sold a net $20.1M in the last 12 months (the 12 months before: -$3.3M).

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 5 sales, $6.8M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026Richard Bryan RiggsbeeDirectorSellplanned in advance (10b5-1)5,285$74.77$395KForm 4
16 Nov 2026Michael GoldbergDirectorSellplanned in advance (10b5-1)13,800$79.15$1.1MForm 4
16 Nov 2026Keith KennedyCFO & COOSellplanned in advance (10b5-1); after exercising options2,097$79.29$166KForm 4
12 Nov 2026Jeffrey Adam NovackSecretary and General CounselSellplanned in advance (10b5-1)4,096$81.13$332KForm 4
9 Nov 2026Keith KennedyCFO & COOSellplanned in advance (10b5-1); after exercising options61,961$77.82$4.8MForm 4
6 Aug 2026Jeffrey Adam NovackSecretary and General CounselSellplanned in advance (10b5-1)2,688$46.26$124KForm 4
6 Aug 2026George BickerstaffDirectorSell20,000$46.29$926KForm 4
6 Aug 2026Christine CournoyerDirectorSellplanned in advance (10b5-1)16,000$46.94$751KForm 4

304 institutions reported shares at the end of Q3 2026, 99% of the shares outstanding; 95 opened a position, 22 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.4.9M9.27%$316.7M+57K+1.2%
State Street Corp2.6M4.99%$170.5M+154K+6.2%
Vanguard Capital Management LLC2.2M4.17%$142.6M-3,925-0.2%
Arrowstreet Capital, Limited Partnership2.1M3.92%$133.9M+1.7M+453%
Blue Water Life Science Advisors, LP1.7M3.31%$113.1M+550K+46%
ARK Investment Management LLC1.6M3.06%$104.6M-344K-18%
Bamco Inc1.5M2.85%$97.5M-437K-23%
Geode Capital Management, LLC1.5M2.82%$96.3M+153K+11%
Divisadero Street Capital Management, LP1.4M2.70%$92.3M+719K+103%
Chevy Chase Trust Holdings, LLC1.4M2.57%$87.9M-85K-5.9%

Federal contracts

All 4 federal contracts

2 new awards in 12 months, $4.1M obligated when signed. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
14 Sep 2026Department of Veterans Affairs$2.5MTRANSPLANT TESTING KITSUSAspending
22 Jan 2026Department of Veterans Affairs$1.6Mup to $1.6MTRANSPLANT TESTING KITSUSAspending
1 Oct 2024Department of Veterans Affairs$2.4MTRANSPLANT TESTING KITSUSAspending
25 Sep 2023Department of Veterans Affairs$1.0MALLOSURE KIDNEY TESTING KITSUSAspending

Company events

All 82 company events

In 12 months: 2 major agreements, 1 director or officer change, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
7 Jul 2026Completed an acquisition or asset sale8-K
15 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
28 Apr 2026Signed a major agreement8-K
16 Apr 2026Signed a major agreement8-K
24 Oct 2025Director or officer change8-K
6 Aug 2025Director or officer change8-K
12 Jun 2025Director or officer changeSame filing: shareholder vote results8-K
28 Mar 2025Director or officer change8-K

61 open postings; careers site tracked since 20 Nov 2026. Most in Sales & business development 46%, Marketing & communications 26%, Research & science 7%, Customer success & support 5%.

PostedJobLocation
20 Nov 2026Manager, Remote Care NavigatorSupply chain & procurementRemote
19 Nov 2026Sr Technical Project ManagerProgram & project managementRemote
18 Nov 2026Sr. Customer Experience Trainer ManagerCustomer success & supportUnited States
18 Nov 2026Clinical Liaison, Specialty Oncology - MN/WIMarketing & communicationsRemote
18 Nov 2026Clinical Liaison, Specialty Oncology - MA/PAMarketing & communicationsRemote
18 Nov 2026Manager, Customer ExperienceCustomer success & supportBrisbane, CA
15 Nov 2026Manager, Customer ExperienceCustomer success & supportUnited States
12 Nov 2026Clinical Liaison, Cell Therapy & TransplantMarketing & communicationsUnited States

Reported lobbying spend: $30K in Q3 2026, $90K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Oct 2026NewTiber Creek Groupfor Caredx, Inc.Issues related to access and payment for post-transplant monitoring tests.Health issuesFiling
30 Sep 2025EndedCura Strategiesfor CaredxLiving organ donation policies and coverage for innovative transplant diagnosticsHealth issuesFiling
30 Sep 2025EndedNet Centric Alliance LLCfor Brownstein Hyatt Farber Schreck, LLP Obo Caredx, Inc.Use of bioscience markers with regard to organ transplant rejectionHealth issuesFiling
30 Jul 2025NewCaredx, Inc.its own lobbyistsIssues related to coverage and payment of laboratory testing.Medicare/MedicaidFiling
31 May 2025EndedActum I, LLCfor Caredx, Inc.Not statedFiling
31 Dec 2024EndedMr. Matthew R. Simmonsfor CaredxNot statedFiling
1 Jun 2024EndedTGB Strategies LLCfor Brownstein Hyatt Farber Schreck Obo Caredx, Inc.Not statedFiling
27 Nov 2023NewActum I, LLCfor Caredx, Inc.Medicare coverage for innovative diagnostic testingHealth issues, Medicare/MedicaidFiling

The 5 newest of 155 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Nov 2026confirmed

Confirmed across sources Institutional holdings and Filings + Financials

CareDx (CDNA): reported revenue of $139.4M for the quarter ended 30 Sep 2026, 1.4× the same quarter last year, while it saw 96 13F filers open a new position in the quarter ended 30 Sep 2026, 3.0× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Financials: Quarterly revenue change, became public on 3 Nov 2026
  • Institutional holdings: Many funds opening a new position, became public on 16 Nov 2026
2024-09-30: $82.9M2024-12-31: $86.6M2025-03-31: $84.7M2025-06-30: $86.7M2025-09-30: $100.1M2025-12-31: $108.4M2026-03-31: $117.7M2026-06-30: $131.9M2026-09-30: $139.4M
The quarter ended 30 Sep 2026 against the 8 quarters before it. this quarterearliernormal: $93.4M
See the evidence (2 changes)

Financials: Quarterly revenue change became public on 3 Nov 2026

CareDx reported revenue of $139.4M for the quarter ended 30 Sep 2026, 1.4× the same quarter last year.

This period
$139.4M (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
$93.4M
Typical spread (median absolute deviation)
$9.6M
How far from its usual level
+3.2
Same quarter last year
$100.1M
History used
4,931 days
2024-09-30: $82.9M2024-12-31: $86.6M2025-03-31: $84.7M2025-06-30: $86.7M2025-09-30: $100.1M2025-12-31: $108.4M2026-03-31: $117.7M2026-06-30: $131.9M2026-09-30: $139.4M
the quarter ended 30 Sep 20268 earlier quartersnormal: $93.4M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Institutional holdings: Many funds opening a new position became public on 16 Nov 2026

CareDx saw 96 13F filers open a new position in the quarter ended 30 Sep 2026, 3.0× the same quarter last year.

This period
96 (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
33
Typical spread (median absolute deviation)
8
How far from its usual level
+5.3
Same quarter last year
32
History used
4,383 days
2024-09-30: 592024-12-31: 272025-03-31: 362025-06-30: 232025-09-30: 322025-12-31: 342026-03-31: 172026-06-30: 512026-09-30: 96
the quarter ended 30 Sep 20268 earlier quartersnormal: 33

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

12 Mar 2019confirmed

Confirmed across sources Filings + Financials and Lobbying

CareDx (CDNA): lobbying on a new issue, while it reported revenue of $23.5M for the quarter ended 31 Dec 2018, 1.9× the same quarter last year. Two unrelated kinds of activity within 6 days.

  • Lobbying: Lobbying on a new issue, became public on 6 Mar 2019
  • Financials: Quarterly revenue change, became public on 12 Mar 2019
2016-12-31: $10.9M2017-03-31: $11.6M2017-06-30: $12.0M2017-09-30: $12.2M2017-12-31: $12.5M2018-03-31: $14.1M2018-06-30: $17.8M2018-09-30: $21.2M2018-12-31: $23.5M
The quarter ended 31 Dec 2018 against the 8 quarters before it. this quarterearliernormal: $12.3M
See the evidence (2 changes)

Lobbying: Lobbying on a new issue became public on 6 Mar 2019

CareDx lobbying on a new issue.

New
['HCR']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
12656554

Financials: Quarterly revenue change became public on 12 Mar 2019

CareDx reported revenue of $23.5M for the quarter ended 31 Dec 2018, 1.9× the same quarter last year.

This period
$23.5M (the quarter ended 31 Dec 2018)
Normal quarter (median of 8 earlier)
$12.3M
Typical spread (median absolute deviation)
$1.1M
How far from its usual level
+6.7
Same quarter last year
$12.5M
History used
2,101 days
2016-12-31: $10.9M2017-03-31: $11.6M2017-06-30: $12.0M2017-09-30: $12.2M2017-12-31: $12.5M2018-03-31: $14.1M2018-06-30: $17.8M2018-09-30: $21.2M2018-12-31: $23.5M
the quarter ended 31 Dec 20188 earlier quartersnormal: $12.3M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 17 Nov 2026several at once

    reported revenue of $139.4M for the quarter ended 30 Sep 2026, 1.4× the same quarter last year, while it saw 96 13F filers open a new position in the quarter ended 30 Sep 2026, 3.0× the same quarter last year. Two unrelated kinds of activity within 14 days.

    See the evidence (2 changes)

    Financials: Quarterly revenue change became public on 3 Nov 2026

    CareDx reported revenue of $139.4M for the quarter ended 30 Sep 2026, 1.4× the same quarter last year.

    This period
    $139.4M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $93.4M
    Typical spread (median absolute deviation)
    $9.6M
    How far from its usual level
    +3.2
    Same quarter last year
    $100.1M
    History used
    4,931 days
    2024-09-30: $82.9M2024-12-31: $86.6M2025-03-31: $84.7M2025-06-30: $86.7M2025-09-30: $100.1M2025-12-31: $108.4M2026-03-31: $117.7M2026-06-30: $131.9M2026-09-30: $139.4M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $93.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Institutional holdings: Many funds opening a new position became public on 16 Nov 2026

    CareDx saw 96 13F filers open a new position in the quarter ended 30 Sep 2026, 3.0× the same quarter last year.

    This period
    96 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    33
    Typical spread (median absolute deviation)
    8
    How far from its usual level
    +5.3
    Same quarter last year
    32
    History used
    4,383 days
    2024-09-30: 592024-12-31: 272025-03-31: 362025-06-30: 232025-09-30: 322025-12-31: 342026-03-31: 172026-06-30: 512026-09-30: 96
    the quarter ended 30 Sep 20268 earlier quartersnormal: 33

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  2. 16 Nov 2026Institutional holdings change

    saw 96 13F filers open a new position in the quarter ended 30 Sep 2026, 3.0× the same quarter last year.

    Same quarter last year: 32; its normal quarter is 33.

    See the evidence
    This period
    96 (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    33
    Typical spread (median absolute deviation)
    8
    How far from its usual level
    +5.3
    Same quarter last year
    32
    History used
    4,383 days
    2024-09-30: 592024-12-31: 272025-03-31: 362025-06-30: 232025-09-30: 322025-12-31: 342026-03-31: 172026-06-30: 512026-09-30: 96
    the quarter ended 30 Sep 20268 earlier quartersnormal: 33

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  3. 16 Nov 2026Lobbying record

    CAREDX, INC.: new lobbying registration (TIBER CREEK GROUP) (dated 1 Oct 2026)

  4. 3 Nov 2026Financials change

    reported revenue of $139.4M for the quarter ended 30 Sep 2026, 1.4× the same quarter last year.

    Same quarter last year: $100.1M; its normal quarter is $93.4M.

    See the evidence
    This period
    $139.4M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $93.4M
    Typical spread (median absolute deviation)
    $9.6M
    How far from its usual level
    +3.2
    Same quarter last year
    $100.1M
    History used
    4,931 days
    2024-09-30: $82.9M2024-12-31: $86.6M2025-03-31: $84.7M2025-06-30: $86.7M2025-09-30: $100.1M2025-12-31: $108.4M2026-03-31: $117.7M2026-06-30: $131.9M2026-09-30: $139.4M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $93.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  5. 20 Sep 2026Government contracts record

    CAREDX, INC.: new Department of Veterans Affairs contract 36C25226N0586 ($2.5M) (dated 14 Sep 2026)

  6. 4 Aug 2026Financials change

    reported revenue of $131.9M for the quarter ended 30 Jun 2026, 1.5× the same quarter last year.

    Same quarter last year: $86.7M; its normal quarter is $89.5M.

    See the evidence
    This period
    $131.9M (the quarter ended 30 Jun 2026)
    Normal quarter (median of 8 earlier)
    $89.5M
    Typical spread (median absolute deviation)
    $5.7M
    How far from its usual level
    +4.7
    Same quarter last year
    $86.7M
    History used
    4,839 days
    2024-06-30: $92.3M2024-09-30: $82.9M2024-12-31: $86.6M2025-03-31: $84.7M2025-06-30: $86.7M2025-09-30: $100.1M2025-12-31: $108.4M2026-03-31: $117.7M2026-06-30: $131.9M
    the quarter ended 30 Jun 20268 earlier quartersnormal: $89.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  7. 7 Jul 2026Filings record

    Completed an acquisition or asset sale

  8. 15 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 15 Jun 2026Filings record

    Director or officer change

  10. 30 Apr 2026Financials change

    reported revenue of $117.7M for the quarter ended 31 Mar 2026, 1.4× the same quarter last year.

    Same quarter last year: $84.7M; its normal quarter is $86.6M.

    See the evidence
    This period
    $117.7M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    $86.6M
    Typical spread (median absolute deviation)
    $4.7M
    How far from its usual level
    +3.6
    Same quarter last year
    $84.7M
    History used
    3,652 days
    2024-03-31: $72.0M2024-06-30: $92.3M2024-09-30: $82.9M2024-12-31: $86.6M2025-03-31: $84.7M2025-06-30: $86.7M2025-09-30: $100.1M2025-12-31: $108.4M2026-03-31: $117.7M
    the quarter ended 31 Mar 20268 earlier quartersnormal: $86.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  11. 28 Jan 2026Government contracts record

    CAREDX, INC.: new Department of Veterans Affairs contract 36C25226N0079 ($1.6M) (dated 22 Jan 2026)

  12. 24 Oct 2025Filings record

    Director or officer change

  13. 20 Oct 2025Lobbying record

    CAREDX: lobbying engagement terminated (CURA STRATEGIES) (dated 30 Sep 2025)

  14. 13 Oct 2025Lobbying record

    BROWNSTEIN HYATT FARBER SCHRECK, LLP OBO CAREDX, INC.: lobbying engagement terminated (NET CENTRIC ALLIANCE LLC) (dated 30 Sep 2025)

  15. 15 Sep 2025Lobbying record

    CAREDX, INC.: new lobbying registration (in-house) (dated 30 Jul 2025)

  16. 6 Aug 2025Filings record

    Director or officer change

  17. 20 Jul 2025Lobbying record

    CAREDX, INC.: lobbying engagement terminated (ACTUM I, LLC) (dated 31 May 2025)

  18. 12 Jun 2025Filings record

    Director or officer change

  19. 14 May 2025Lobbying record

    CAREDX: lobbying engagement terminated (MR. MATTHEW R. SIMMONS) (dated 31 Dec 2024)

  20. 28 Mar 2025Filings record

    Director or officer change

  21. 8 Jan 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 8 Jan 2025Filings record

    Director or officer change

  23. 14 Nov 2024Institutional holdings change

    saw 59 13F filers open a new position in the quarter ended 30 Sep 2024, 4.9× the same quarter last year.

    Same quarter last year: 12; its normal quarter is 18.5.

    See the evidence
    This period
    59 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    18.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +10.9
    Same quarter last year
    12
    History used
    3,653 days
    2022-09-30: 222022-12-31: 202023-03-31: 182023-06-30: 172023-09-30: 122023-12-31: 192024-03-31: 142024-06-30: 272024-09-30: 59
    the quarter ended 30 Sep 20248 earlier quartersnormal: 18.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  24. 7 Oct 2024Government contracts record

    CAREDX, INC.: new Department of Veterans Affairs contract 36C25225N0010 ($2.4M) (dated 1 Oct 2024)

  25. 4 Oct 2024Filings record

    Director or officer change

  26. 12 Sep 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  27. 12 Sep 2024Filings record

    Director or officer change

  28. 25 Jul 2024Lobbying record

    BROWNSTEIN HYATT FARBER SCHRECK OBO CAREDX, INC.: lobbying engagement terminated (TGB STRATEGIES LLC) (dated 1 Jun 2024)

  29. 16 Apr 2024Filings record

    Director or officer change

  30. 11 Mar 2024Filings record

    Director or officer change

  31. 12 Feb 2024Lobbying record

    CAREDX: new lobbying registration (MR. MATTHEW R. SIMMONS) (dated 5 Nov 2023)

  32. 22 Jan 2024Lobbying record

    BROWNSTEIN HYATT FARBER SCHRECK, LLP OBO CAREDX, INC.: new lobbying registration (NET CENTRIC ALLIANCE LLC) (dated 1 Oct 2023)

  33. 9 Jan 2024Lobbying record

    CAREDX, INC.: new lobbying registration (ACTUM I, LLC) (dated 27 Nov 2023)

  34. 22 Dec 2023Filings record

    Director or officer change

  35. 1 Nov 2023Filings record

    Director or officer change

  36. 1 Oct 2023Government contracts change

    won its first federal award in our data, a $1.0M Department of Veterans Affairs contract.

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2007
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  37. 1 Oct 2023Government contracts record

    CAREDX, INC.: new Department of Veterans Affairs contract 36C25223N0621 ($1.0M) (dated 25 Sep 2023)

  38. 26 Sep 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 26 Sep 2023Filings record

    Director or officer change

  40. 23 Nov 2022Filings record

    Director or officer change

Showing the newest 40 of 130 entries; narrow the window or the kind of data to see older ones.

Not listed: 354 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001217234
Ticker
CDNA
Domain
caredx.com
Employer name
CareDx, Inc. (1 unverified)
Hq location
CA|BRISBANE|94005 (1 unverified)
Lobbying client
brownstein hyatt farber schreck llp obo caredx, brownstein hyatt farber schreck obo caredx, caredx
Name
CareDx, Inc., CareDx Lab Solutions, Inc, CareDx Transplant Management, Inc, EXPRESSION DIAGNOSTICS INC and 2 more
Uei
JW1HCXNLBEA7, KHHBJ9FJR225, Y371A27ZEUM4
Wikidata
Q106238469
  • DOL H-1B labor condition applications and PERM certifications313 data points6 Jan 2020 to 17 Aug 2026
  • Federal lobbying disclosures (LDA)18 records, 115 data points2 Oct 2015 to 1 Oct 2026
  • SEC Form 13F institutional holdings441 data points30 Sep 2014 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)223 records12 Feb 2016 to 29 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)917 data points31 Dec 2011 to 26 Oct 2026
  • SEC Form 4 insider transactions211 records, 684 data points18 Apr 2016 to 18 Nov 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards4 records, 549 data points31 Oct 2008 to 6 Nov 2026